CORRESP

0001193125-20-290355.txt : 20201211 0001193125-20-290355.hdr.sgml : 20201211 20201110173951 ACCESSION NUMBER: 0001193125-20-290355 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 CORRESP 1 filename1.htm CORRESP

[LETTERHEAD OF INMED PHARMACEUTICALS INC.]

November 10, 2020

VIA EDGAR

Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549-7010

USA

Re:

InMed Pharmaceuticals Inc.

Registration Statement on Form S-1

Filed June 19, 2020, as amended

File No. 333-239319

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Securities Act”), InMed Pharmaceuticals Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) to November 12, 2020 at 9:00 a.m. (Eastern) or as soon thereafter as is practicable.

The Company also requests the Commission confirm the effective date and time of the Registration Statement in writing.


INMED PHARMACEUTICALS INC.

By		/s/ Eric A. Adams
		Name: Eric A. Adams Title: President & Chief Executive Officer